Overview of Dr. Osman
Dr. Keren Osman is a hematologist in New York, NY and is affiliated with The Mount Sinai Hospital. She received her medical degree from Icahn School of Medicine at Mount Sinai and has been in practice 21 years. She is one of 52 doctors at The Mount Sinai Hospital who specialize in Hematology. She has more than 30 publications and over 500 citings.
Office
10 E 102nd St
New York, NY 10029Fax+1 212-731-5210
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1996 - 1999- Icahn School of Medicine at Mount SinaiClass of 1996
Certifications & Licensure
NY State Medical License 1997 - 2026
Clinical Trials
- Host Dendritic Cells in Allograft Patients Start of enrollment: 2009 Aug 01
- Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Start of enrollment: 2013 Jan 01
- Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis Start of enrollment: 2017 Jun 12
Publications & Presentations
PubMed
- 23 citationsPatient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.Mahmoud Elsawy, Julio C Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson
Blood. 2022-11-24 - 163 citationsVigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy.Joseph Krasovsky, Keren Osman, Matthew D. Geller
The Journal of Experimental Medicine. 2003-12-01 - 54 citationsInsights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myelomaCyrus V. Hedvat, Raymond L. Comenzo, Julie Teruya-Feldstein, Adam B. Olshen, Scott Ely
British Journal of Haematology. 2003-09-01
Abstracts/Posters
- A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...Keren Osman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...Keren Osman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
The Covid Drug Wars That Pitted Doctors vs. DoctorAugust 5th, 2020
Mount Sinai Leading the Way in Innovative Stem Cell Therapy for COVID-19 PatientsApril 9th, 2020
Regimen Deemed ‘Safe and Feasible’ in MMFebruary 23rd, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
